Clinical Trials Logo

Essential Tremor clinical trials

View clinical trials related to Essential Tremor.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT02668146 Active, not recruiting - Essential Tremor Clinical Trials

An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor

Start date: October 2015
Phase: Phase 2
Study type: Interventional

Obtain information on whether the medication Perampanel reduces tremor in people with essential tremor and is well-tolerated.

NCT ID: NCT02649166 Active, not recruiting - Essential Tremor Clinical Trials

Responsive Deep Brain Stimulator for Essential Tremor

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

Essential tremor is an incurable, degenerative brain disorder that results in increasingly debilitating tremor, and afflicts an estimated 7 million people in the US. In one study, 25% of essential tremor patients were forced to change jobs or take early retirement because of tremor. Essential tremor is directly linked to progressive functional impairment, social embarrassment, and even depression. The tremor associated with essential tremor is typically slow, involves the hands (and sometimes the head and voice), worsens with intentional movements, and is insidiously progressive over many years. Deep brain stimulation has emerged as a highly effective treatment for intractable, debilitating essential tremor. However, since the intention tremor of essential tremor is typically intermittent, and commonly absent at rest, the currently available continuous deep brain stimulation may be delivering unnecessary current to the brain that increases undesirable side effects such as slurred speech and walking difficulty, and hastens the depletion of device batteries, necessitating more frequent surgical procedures to replace spent pulse generators. The overall objective of this early feasibility study is to provide preliminary data on the safety and efficacy of "closed-loop" deep brain stimulation for intention tremor using novel deep brain stimulation devices capable of continuously sensing brain activity and delivering therapeutic stimulation only when necessary to suppress tremor.

NCT ID: NCT02551848 Active, not recruiting - Essential Tremor Clinical Trials

Kinematic-based BoNT-A Injections for Bilateral ET

Start date: August 2014
Phase: Phase 2
Study type: Interventional

The primary objective is to study the efficacy of botulinum toxin type A (Xeomin®) injected utilizing kinematically-based injection parameters for the treatment of upper extremity essential tremor (ET). Additional objectives are to study the benefit of kinematic assessment tools in determining injection parameters and to study the composition of tremor using kinematics.

NCT ID: NCT02289560 Active, not recruiting - Essential Tremor Clinical Trials

Continued Access Protocol: ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors

Start date: April 2015
Phase: N/A
Study type: Interventional

The objective of this prospective, multi site, single-arm study is to capture the efficacy of treatment using the ExAblate Transcranial System and to further demonstrate safety in medication-refractory tremor in patients with essential tremor (ET).

NCT ID: NCT02255929 Active, not recruiting - Essential Tremor Clinical Trials

Gamma Knife Radiosurgery for Treatment of Essential Tremor

Start date: September 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to examine effects (good and bad) of gamma knife radiosurgery for essential tremor. The gamma knife places a small lesion in the brain to suppress tremors.

NCT ID: NCT02252380 Active, not recruiting - Parkinson's Disease Clinical Trials

ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

Start date: May 2015
Phase: N/A
Study type: Interventional

The proposed study is to evaluate the effectiveness of ExAblate Transcranial MRgFUS as a tool for creating a unilateral lesion in the Vim thalamus or the globus pallidus (GPi) in patients with treatment-refractory symptoms of movement disorders.